UMIN-CTR History
Name： UMIN ID：
| Unique ID issued by UMIN | UMIN000003135 |
|---|---|
| Receipt number | R000003741 |
| Scientific Title | Randomized phase II study of bortezomib plus dexamethasone (BD) versus thalidomide plus dexamethasone (TD) for relapsed or refractory multiple myeloma (JCOG0904, r II BD vs TD for MM) |
| Date of disclosure of the study information | 2010/02/03 |
| Last modified on | 2022/08/30 16:51:08 |
| No. | Disposal | Last modified on | Item of update | |
|---|---|---|---|---|
| 1 | Insert | 2010/02/03 13:34:30 | ||
| 2 | Update | 2011/08/03 12:26:06 | Name of person sending information Name of person sending information Post marketing survey by drug manufacture etc., specified by Japanese law. |
|
| 3 | Update | 2011/08/03 12:31:15 | Key inclusion criteria Key inclusion criteria Key exclusion criteria |
|
| 4 | Update | 2012/05/28 15:41:21 | Institutions |
|
| 5 | Update | 2012/06/20 11:39:28 | Acronym Acronym |
|
| 6 | Update | 2012/10/22 13:29:42 | Institutions |
|
| 7 | Update | 2014/08/20 11:50:38 | Key inclusion criteria Key inclusion criteria Target sample size |
|
| 8 | Update | 2014/08/20 11:52:43 | Division name Division name TEL Division name Division name TEL Institutions |
|
| 9 | Update | 2014/08/20 11:53:46 | Anticipated trial start date Last follow-up date |
|
| 10 | Update | 2014/10/24 17:24:06 | Recruitment status |
|
| 11 | Update | 2022/08/30 16:51:08 | Recruitment status Date of IRB |
